Akebia Therapeutics, Inc.
A maker of medicines for people with kidney disease, Akebia developed Vafseo, an oral pill that treats anemia in adults on dialysis, and also sells Auryxia for kidney patients. Founded in 2007 in Cambridge, Massachusetts, the company grew through a merger with Keryx Biopharmaceuticals. Its name comes from the Akebia plant, a fragrant flowering vine nicknamed the "chocolate vine" for its sweet, vanilla-like scent.
Granted 2.81M · Bought 69.3K · Sold 872.3K
Granted 1.06M · Sold 294.6K
Granted 748.9K · Sold 76.3K
Granted 599.3K · Sold 201.8K
Granted 499.3K · Sold 129.4K
Granted 702.2K · Sold 140.4K
Granted 519.3K
Granted 456.2K · Sold 86.5K
Granted 402.9K · Sold 108.1K
Granted 145.1K
Granted 190.8K · Sold 9.8K
Granted 145.1K
Granted 145.1K
Granted 50.0K · Sold 13.2K
Granted 190.0K · Sold 69.8K
Granted 145.1K
Granted 165.2K
Granted 109.4K · Sold 4.6K
Granted 145.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Butler John P.CEO and President, Director · 25 transactions | +199% | 3.53M | 2.81M | 69.3K | 872.3K |
| Burke Steven KeithSVP, Chief Medical Officer · 26 transactions | +455.4% | 948.4K | 1.06M | — | 294.6K |
| Ostrowski ErikSVP, CFO, CBO & Treasurer · 5 transactions | — | 672.6K | 748.9K | — | 76.3K |
| Dahan MichelSVP, Chief Operating Officer · 16 transactions | +153.1% | 672.1Kas of May 2024 | 599.3K | — | 201.8K |
| Hadas Nicole R.SVP, Chief Legal Officer · 16 transactions | +139.2% | 651.2Kas of May 2024 | 499.3K | — | 129.4K |
| Grund NicholasChief Commercial Officer · 6 transactions | — | 561.8K | 702.2K | — | 140.4K |
| Snow EllenSVP, CFO and Treasurer · 2 transactions | — | 519.3Kas of Jan 2024 | 519.3K | — | — |
| Spellman David ASVP, CFO and Treasurer · 9 transactions | +481.3% | 446.5Kas of May 2023 | 456.2K | — | 86.5K |
| Malabre Richard CSVP, Chief Accounting Officer · 9 transactions | — | 312.8K | 402.9K | — | 108.1K |
| Adams AdrianDirector · 5 transactions | +159.3% | 236.2K | 145.1K | — | — |
| Cotreau ViolettaSVP, Chief Accounting Officer · 4 transactions | +465.4% | 220.0Kas of May 2022 | 190.8K | — | 9.8K |
| Rogers Michael WDirector · 5 transactions | +277.3% | 197.4K | 145.1K | — | — |
| Smith CynthiaDirector · 5 transactions | +281.6% | 196.6K | 145.1K | — | — |
| Faulkingham DellSVP, CCO · 4 transactions | +27.6% | 174.8Kas of Mar 2022 | 50.0K | — | 13.2K |
| Rucci Carolyn M.SVP, Chief Legal Officer · 4 transactions | — | 171.8K | 190.0K | — | 69.8K |
| Wolf MylesDirector · 5 transactions | +605.1% | 169.1K | 145.1K | — | — |
| Frieson RonDirector · 6 transactions | — | 165.2K | 165.2K | — | — |
| Gilman Steven CDirector · 5 transactions | +218.4% | 152.8Kas of Jun 2025 | 109.4K | — | 4.6K |
| Zumwalt Leanne MDirector · 5 transactions | — | 145.1K | 145.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.94M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.